Results 251 to 260 of about 55,025 (289)

PARP1 at the crossroad of cellular senescence and nucleolar processes.

Ageing Research Reviews
Senescent cells that occur in response to telomere shortening, oncogenes, extracellular and intracellular stress factors are characterized by permanent cell cycle arrest, the morphological and structural changes of the cell that include the senescence ...
Kinga Kołacz, A. Robaszkiewicz
semanticscholar   +1 more source

ANXA1 promotes tumor immune evasion by binding PARP1 and upregulating Stat3-induced expression of PD-L1 in multiple cancers.

Cancer immunology research, 2023
The deregulation of annexin A1 (ANXA1), a regulator of inflammation and immunity, leads to cancer growth and metastasis. However, whether ANXA1 is involved in cancer immunosuppression is still unclear.
Ding Xiao, Ting Zeng, Wei Zhu, Zheng-Zheng Yu, Wei Huang, Hong Yi, Shan Lu, Juan Feng, Xue-Ping Feng, Di Wu, Qi Wen, Jian-Hua Zhou, Li Yuan, Zhuang Wei, Zhi-Qiang Xiao   +14 more
semanticscholar   +1 more source

Nano-selenium protects grass carp hepatocytes against 4-tert-butylphenol-induced mitochondrial apoptosis and necroptosis via suppressing ROS-PARP1 axis.

Fish and Shellfish Immunology, 2023
4-tert-butylphenol (4-tBP) is a monomer widely used in the synthesis of industrial chemicals, and posed a high risk to aquatic animals. Our study focused on toxic phenotype and mechanism of detoxification in grass carp hepatocytes (L8824) after 4-tBP ...
J. Cui, Minna Qiu, Yuhang Liu, Yuhao Liu, You Tang, X. Teng, Shu Li   +6 more
semanticscholar   +1 more source

Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1.

Clinical Cancer Research, 2023
PURPOSE We evaluated the properties and activity of AZD9574, a blood-brain barrier (BBB) penetrant selective inhibitor of PARP1 and assessed its efficacy and safety alone and in combination with temozolomide (TMZ), in preclinical models.
A. Staniszewska, Domenic Pilger, Sonja J. Gill, K. Jamal, Natacha Bohin, Sofia Guzzetti, Jacob A Gordon, Gregory Hamm, Gill Mundin, G. Illuzzi, A. Pike, Lisa McWilliams, Gareth Maglennon, J. Rose, Glen Hawthorne, Miguel A Cortés González, Christer Halldin, P. Johnström, M. Schou, S. Critchlow, Stephen Fawell, J. Johannes, Elisabetta Leo, Barry R Davies, Sabina Cosulich, J. Sarkaria, M. O’Connor, P. Hamerlik   +27 more
semanticscholar   +1 more source

Geniposide ameliorates atherosclerosis by restoring lipophagy via suppressing PARP1/PI3K/AKT signaling pathway.

Phytomedicine
BACKGROUND Atherosclerosis (AS) is the leading cause of global death, which manifests as arterial lipid stack and plaque formation. Geniposide is an iridoid glycoside extract from Gardenia jasminoides J.Ellis that ameliorates AS by mediating autophagy ...
Jinhai Lin, Xiaolong Wang, Mingyang Gu, Yuanyuan Chen, Jiongbo Xu, Nhi Van Chau, Junlong Li, Xiaodong Ji, Qingmin Chu, Lijin Qing, Wei Wu   +10 more
semanticscholar   +1 more source

Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor.

Journal of Medicinal Chemistry
PARP inhibitors have attracted considerable interest in drug discovery due to the clinical success of first-generation agents such as olaparib, niraparib, rucaparib, and talazoparib. Their success lies in their ability to trap PARP to DNA; however, first-
J. Johannes, Amber Y. S. Balazs, Derek G. Barratt, M. Bista, M. Chuba, S. Cosulich, S. Critchlow, S. Degorce, Paolo Di Fruscia, S. Edmondson, K. Embrey, Stephen Fawell, Avipsa Ghosh, Sonja J. Gill, Anders Gunnarsson, Sudhir M. Hande, T. Heightman, Paul Hemsley, G. Illuzzi, Jordan Lane, C. Larner, Elisabetta Leo, Lina Liu, Andrew Madin, Lisa McWilliams, M. O’Connor, Jonathan Orme, Fiona Pachl, Martin J. Packer, Xiao-wei Pei, A. Pike, Marianne Schimpl, H. She, A. Staniszewska, V. Talbot, Elizabeth Underwood, Jeffrey Varnes, L. Xue, Tieguang Yao, Ke Zhang, Andrew X. Zhang, XiaoLa Zheng   +41 more
semanticscholar   +1 more source

Rational Design of PARP1/c-Met Dual Inhibitors for Overcoming PARP1 Inhibitor Resistance Induced by c-Met Overexpression.

Journal of Medicinal Chemistry
The emergence of resistance to PARP1 inhibitors poses a current therapeutic challenge, necessitating the development of novel strategies to overcome this obstacle.
Zeren Sun, Lanjie Li, Bingxin Zhai, Mengxuan Hu, Lei-ming Huang, Shi-Hui Huang, L. Ye, Xiangying Kong, Jie Xu, J. Bai, Jingjie Yan, Qichen Zhou, Zheqi Hu, Yuchen Zhang, Yuhan Jiang, Yan Zhang, Zhou Qiao, Yi Zou, Yungen Xu, Qihua Zhu   +19 more
semanticscholar   +1 more source

Pimpinellin ameliorates macrophage inflammation by promoting RNF146‐mediated PARP1 ubiquitination

Phytotherapy Research
Macrophage inflammation plays a central role during the development and progression of sepsis, while the regulation of macrophages by parthanatos has been recently identified as a novel strategy for anti‐inflammatory therapies. This study was designed to
Liuye Yang, Meng Du, Kaiyuan Liu, Pengchao Wang, Jingbo Zhu, Fengcen Li, Ze Wang, Kai Huang, Minglu Liang   +8 more
semanticscholar   +1 more source

Transcriptional regulation mechanism of PARP1 and its application in disease treatment

Epigenetics & Chromatin
Poly (ADP-ribose) polymerase 1 (PARP1) is a multifunctional nuclear enzyme that catalyzes poly-ADP ribosylation in eukaryotic cells. In addition to maintaining genomic integrity, this nuclear enzyme is also involved in transcriptional regulation.
Yu Lu, Wenliang Fu, Weiwei Xing, Haowei Wu, Chao Zhang, Donggang Xu   +5 more
semanticscholar   +1 more source

PARP1: A potential biomarker for gastric cancer

Pathology - Research and Practice, 2019
Gastric cancer (GC) is the third leading cause of cancer mortality worldwide, with an overall 5-y survival rate of 25%. The majority of GCs are caused by infectious agents, including the bacterium Helicobacter pylori (H. pylori) and Epstein-Barr virus (EBV).
Hifza, Afzal, Shahzad, Yousaf, Faisal, Rahman, Malik Waqar, Ahmed, Zertashia, Akram, Mahmood, Akhtar Kayani, Ishrat, Mahjabeen   +6 more
openaire   +2 more sources